18
Participants
Start Date
December 15, 2021
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
ASTX727
Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
NOT_YET_RECRUITING
START Barcelona - Hospital HM Nou Delfos, Barcelona
RECRUITING
Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu, Bucharest
NOT_YET_RECRUITING
START Rioja - Hospital de San Pedro, La Rioja
NOT_YET_RECRUITING
START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid
NOT_YET_RECRUITING
START Madrid - CIOCC - HM Sanchinarro, Madrid
NOT_YET_RECRUITING
Hospital Clínico Universitario Virgen de la Arrixaca (Hematology Dept), Murcia
NOT_YET_RECRUITING
MD Anderson, Houston
RECRUITING
Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca
RECRUITING
Erebuni Medical Center, Yerevan
RECRUITING
Hematology Center After Prof. R. Yeolyan (Adult Blood Disorders), Yerevan
RECRUITING
Hematology Center After Prof. R. Yeolyan (Clinic of Adults Oncology), Yerevan
RECRUITING
National Center of Oncology Named After V.A. Fanarjyan, Yerevan
WITHDRAWN
Complex Oncology Center - Plovdiv - Base II, Plovdiv
WITHDRAWN
BIO1, Vilnius
WITHDRAWN
Hospital Universitari Dexeus - Grupo Quirónsalud, Barcelona
RECRUITING
Hospital Universitari Arnau de Vilanova, Lleida
WITHDRAWN
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Hospital Clínico Universitario Virgen de la Arrixaca (Solid Tumor Dept), Murcia
TERMINATED
Hospital Universitari i Politècnic La Fe, Valencia
RECRUITING
Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p., Wroclaw
RECRUITING
Summit Clinical Research s.r.o, Bratislava
Taiho Oncology, Inc.
INDUSTRY